| Fabry Disease
Elfabrio vs Fabrazyme
Side-by-side clinical, coverage, and cost comparison for fabry disease.Deep comparison between: Elfabrio vs Fabrazyme with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsFabrazyme has a higher rate of injection site reactions vs Elfabrio based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Fabrazyme but not Elfabrio, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Elfabrio
Fabrazyme
At A Glance
IV infusion
Every 2 weeks
Alpha-galactosidase A enzyme replacement
IV infusion
Every 2 weeks
Enzyme replacement therapy
Indications
- Fabry Disease
- Fabry Disease
Dosing
Fabry Disease 1 mg/kg administered by IV infusion every 2 weeks; initial infusion rates are weight-based with separate schedules for ERT-experienced and ERT-naive patients.
Fabry Disease 1 mg/kg body weight infused every two weeks as an IV infusion; initial infusion rate 0.25 mg/min (15 mg/hour); for patients >=30 kg, rate may be increased in increments of 0.05-0.08 mg/min with each subsequent infusion as tolerated.
Contraindications
—
—
Adverse Reactions
Most common (>=15%) infusion-associated reactions, nasopharyngitis, headache, diarrhea, fatigue, nausea, back pain, pain in extremity, sinusitis
Serious hypersensitivity reactions including anaphylaxis, infusion-associated reactions, membranoproliferative glomerulonephritis
Most common (>=5%) Upper respiratory tract infection, chills, pyrexia, headache, cough, paresthesia, fatigue, peripheral edema, dizziness, rash, pain in extremity, myalgia, lower respiratory tract infection, pain, back pain, hypertension, pruritus, tachycardia, excoriation, increased blood creatinine, tinnitus, dyspnea, fall, burning sensation, anxiety, depression, wheezing, hypoacusis, chest discomfort, fungal infection, viral infection, hot flush.
Serious Hypersensitivity reactions including anaphylaxis, infusion-associated reactions.
Postmarketing Cardiorespiratory arrest, cardiac failure, myocardial infarction, anaphylaxis, angioedema, bronchospasm, cerebrovascular accident, respiratory failure, renal failure, leukocytoclastic vasculitis.
Pharmacology
Alpha-galactosidase A enzyme replacement; pegunigalsidase alfa-iwxj is internalized and transported into lysosomes where it reduces accumulated globotriaosylceramide (Gb3) caused by alpha-galactosidase A deficiency in Fabry disease.
Agalsidase beta provides an exogenous source of alpha-galactosidase A; it is internalized and transported into lysosomes where it exerts enzymatic activity and reduces accumulated globotriaosylceramide (GL-3) in Fabry disease patients.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Elfabrio
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
Fabrazyme
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Elfabrio
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Fabrazyme
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Elfabrio
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Fabrazyme
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Fabry Disease - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Fabry Disease - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
ElfabrioView full Elfabrio profile
FabrazymeView full Fabrazyme profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.